‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA
Paul Hastings’ day job as CEO of Nkarta has him talking about natural killer cells and their potential applications in cancer. But throughout the pandemic you’ll likely remember him in his other role: As vice chair of BIO, the biotech trade group, he would often sign his name right under chairman (and Ovid CEO) Jeremy Levin, calling for FDA independence, standing up for the right to vote, and encouraging others to speak out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.